GTx (GTXI) Earning Somewhat Positive News Coverage, Study Finds
Media coverage about GTx (NASDAQ:GTXI) has trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. GTx earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.8885470505718 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- BRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29 (reuters.com)
- 13G Filing: Aisling Capital IV, LP and GTx Inc (GTXI) (feedproxy.google.com)
- GO Therapeutics appoints Dr. Robert J. Wills to Board of Directors (globenewswire.com)
- World Capnography Market to Observe Strong Development by 2027 (abnewswire.com)
- Representing GTx Inc. in IP and Patent Matters (lexology.com)
Separately, ValuEngine raised GTx from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th.
GTx (GTXI) traded down 0.24% during mid-day trading on Friday, hitting $8.19. The company had a trading volume of 5,494 shares. The company’s 50 day moving average price is $7.48 and its 200-day moving average price is $5.48. The firm’s market capitalization is $131.52 million. GTx has a 12-month low of $0.65 and a 12-month high of $9.71.
GTx (NASDAQ:GTXI) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter. On average, analysts forecast that GTx will post ($1.16) EPS for the current fiscal year.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.